JP2024537140A5 - - Google Patents

Info

Publication number
JP2024537140A5
JP2024537140A5 JP2024520708A JP2024520708A JP2024537140A5 JP 2024537140 A5 JP2024537140 A5 JP 2024537140A5 JP 2024520708 A JP2024520708 A JP 2024520708A JP 2024520708 A JP2024520708 A JP 2024520708A JP 2024537140 A5 JP2024537140 A5 JP 2024537140A5
Authority
JP
Japan
Prior art keywords
inhibitor
pharmaceutical composition
kras
composition according
sos1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520708A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537140A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/045622 external-priority patent/WO2023059597A1/en
Publication of JP2024537140A publication Critical patent/JP2024537140A/ja
Publication of JP2024537140A5 publication Critical patent/JP2024537140A5/ja
Pending legal-status Critical Current

Links

JP2024520708A 2021-10-05 2022-10-04 Kras g12d阻害剤とsos1阻害剤との併用療法 Pending JP2024537140A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252569P 2021-10-05 2021-10-05
US63/252,569 2021-10-05
PCT/US2022/045622 WO2023059597A1 (en) 2021-10-05 2022-10-04 Combination therapies of kras g12d inhibitors with sos1 inhibitors

Publications (2)

Publication Number Publication Date
JP2024537140A JP2024537140A (ja) 2024-10-10
JP2024537140A5 true JP2024537140A5 (cg-RX-API-DMAC7.html) 2025-10-10

Family

ID=85803684

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520708A Pending JP2024537140A (ja) 2021-10-05 2022-10-04 Kras g12d阻害剤とsos1阻害剤との併用療法

Country Status (10)

Country Link
US (1) US20250000863A1 (cg-RX-API-DMAC7.html)
EP (1) EP4412718A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024537140A (cg-RX-API-DMAC7.html)
KR (1) KR20240089358A (cg-RX-API-DMAC7.html)
CN (1) CN118382459A (cg-RX-API-DMAC7.html)
AU (1) AU2022361380A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233570A1 (cg-RX-API-DMAC7.html)
IL (1) IL311859A (cg-RX-API-DMAC7.html)
MX (1) MX2024004215A (cg-RX-API-DMAC7.html)
WO (1) WO2023059597A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
US20260200925A1 (en) * 2021-11-24 2026-07-16 Merck Sharp & Dohme Llc Small molecule inhibitors of kras mutated proteins
WO2024012456A1 (zh) * 2022-07-12 2024-01-18 南京明德新药研发有限公司 哌嗪桥取代的杂环并嘧啶类化合物
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20260102810A (ko) * 2023-10-25 2026-07-01 컴쿼트 바이오사이언시즈 인크. 세포 증식을 조절하는 방법
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
US20250312351A1 (en) 2024-04-08 2025-10-09 Mirati Therapeutics, Inc. Combination therapies using prmt5 inhibitors and sos1 inhibitors for the treatment of cancer
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer
KR20260059498A (ko) * 2024-10-23 2026-04-30 제일약품주식회사 바이사이클릭 헤테로사이클릴 화합물의 신규 염 및 이의 결정형
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
PH12022551102A1 (en) 2019-11-08 2023-11-20 Revolution Medicines Inc Bicyclic heteroaryl compounds and uses thereof
WO2022076917A1 (en) 2020-10-08 2022-04-14 Kumquat Biosciences Inc. Modulators of cell proliferation and uses thereof
CN117979966A (zh) * 2021-04-09 2024-05-03 锐新医药公司 使用sos1抑制剂和ras抑制剂治疗癌症
WO2023284730A1 (en) * 2021-07-14 2023-01-19 Nikang Therapeutics, Inc. Alkylidene derivatives as kras inhibitors
AU2024361609A1 (en) 2023-10-20 2026-06-04 Mirati Therapeutics, Inc. Crystalline forms of fumarate salt of mrtx0902

Similar Documents

Publication Publication Date Title
JP2024537136A5 (cg-RX-API-DMAC7.html)
JP2025000632A5 (cg-RX-API-DMAC7.html)
JP2022548791A5 (cg-RX-API-DMAC7.html)
JP2025000629A5 (cg-RX-API-DMAC7.html)
JP2024537139A5 (cg-RX-API-DMAC7.html)
JP2025000630A5 (cg-RX-API-DMAC7.html)
JP2024537137A5 (cg-RX-API-DMAC7.html)
JP2024540839A5 (cg-RX-API-DMAC7.html)
FI3849537T3 (fi) Yhdistelmäterapioita
JP2022548255A5 (cg-RX-API-DMAC7.html)
JP2025512999A5 (cg-RX-API-DMAC7.html)
JP2022530866A5 (cg-RX-API-DMAC7.html)
JP2022535577A5 (cg-RX-API-DMAC7.html)
JP2022500385A5 (cg-RX-API-DMAC7.html)
JP2022500388A5 (cg-RX-API-DMAC7.html)
HRP20230377T1 (hr) Inhibitori mutacije kras g12c
JP2024525993A5 (cg-RX-API-DMAC7.html)
IL311834A (en) Combinations of KRAS G12D inhibitors with PI3KA inhibitors and therapeutic methods
CN101850047B (zh) 一种治疗湿疹皮炎的中药组合物及其制剂
IL311863A (en) Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods
IL315645A (en) Combination therapies comprising a sos1 inhibitor and an egfr inhibitor
JP2015528469A (ja) 前立腺の治療のための薬物送達システム及び方法
JP2025513802A5 (cg-RX-API-DMAC7.html)
CN103463180B (zh) 一种痔疮药膏及其制备方法
CN108969642A (zh) 一种治疗慢性前列腺炎的中药复方外用制剂及其制备工艺